Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes

American Journal of Health-System Pharmacy

Volumn 70, Issue 23, 2013, Pages 2097-2103

  Ottney, Anne ^a,b  

^a FERRIS STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; LIRAGLUTIDE; TETRAHYDROLIPSTATIN; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; LACTONE; PEPTIDE; VENOM;

ADULT; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSOMNIA; LIFESTYLE MODIFICATION; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTING ENERGY EXPENDITURE; SATIETY; SELF ESTEEM; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; DOSE RESPONSE; DRUG POTENTIATION; LIFESTYLE; OBESITY; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCAGON-LIKE PEPTIDE 1; HUMANS; LACTONES; LIFE STYLE; OBESITY; PEPTIDES; RECEPTORS, GLUCAGON; TREATMENT OUTCOME; VENOMS; WEIGHT LOSS;

EID: 84891373349     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130081     Document Type: Article

References (30)

1. National Center for Health Statistics. Health, United States, 2011 with special feature on socioeconomic status and health. www.cdc.gov/nchs/data/hus/hus11.pdf#069 (accessed 2013 Feb 5).
2. National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. NIH publication no. 98-4083. www.nhlbi.nih.gov/guidelines/obesity/ob-gdlns.pdf (accessed 2013 Aug 28).
3. Stewart ST, Cutler DM, Rosen AB. Fore-casting the effects of obesity and smoking on U.S. life expectancy. N Engl J Med. 2009; 361:2252-60.
4. Snow V, Barry P, Fitterman N et al. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2005; 142:525-31.
5. Mechanick JI, Youdim A, Jones DB et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient - 2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic and Bariatric Surgery. Endocr Pract. 2013:e1-36.
6. Colman E, Golden J, Roberts M et al. The FDA's assessment of two drugs for chronic weight management. N Engl J Med. 2012; 367:1577-9.
7. Glandt M, Raz I. Present and future: pharmacologic treatment of obesity. J Obes. 2011; 2011:636181.
8. Rothman RB, Baumann MH. Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf. 2009; 8:317-29.
9. Tong J, Sandoval DA. Is the GLP-1 system a viable therapeutic target for weight reduction? Rev Endocr Metab Disord. 2011;12:187-95.
10. Vilsbøll T, Christensen M, Junker AE et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomized controlled trials. BMJ. 2012;344:d7771.
11. Flint A, Raben A, Astrup A et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998; 101:515-20.
12. Flint A, Raben A, Ersbøll AK et al. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord. 2001; 25:781-92.
13. Astrup A, Rössner S, Van Gaal L et al. Liraglutide for weight loss with obese people - author's reply. Lancet. 2010; 375:552-3. Letter.
14. Bray GA. Gastrointestinal hormones and weight management. Lancet. 2009; 374:1570-1.
15. Food and Drug Administration. Guidance for industry: developing products for weight management (draft guidance). www.fda.gov/downloads/Drugs/.../Guidances/ucm071612.pdf (accessed 2013 Feb 3).
16. Rosenstock J, Klaff LJ, Schwartz S et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care. 2010; 33:1173-5.
17. Dushay J, Gao C, Gopalakrishnan GS et al. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care. 2012; 35:4-11.
18. Astrup A, Rössner S, Van Gaal L et al. Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo-controlled study. Lancet. 2009; 374:1606-16.
19. Astrup A, Carraro R, Finer N et al. Safety, tolerability, and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes. 2012; 36:843-54.
20. Wadden TA, Hollander P, Klein S et al. Liraglutide provides weight maintenance and additional weight loss after low calorie diet-induced weight loss in obese subjects without diabetes: the SCALE maintenance study. Diabetes. 2011; 60:A502. Abstract.
21. ClinicalTrials.gov. Comparison of liraglutide versus placebo in weight loss maintenance in obese subjects: SCALE-maintenance. www.clinicaltrials.gov/ct2/ show/NCT00781937?term=Comparison+of+liraglutide+versus+placebo+in+weight+loss+maintenance+in+obese+subjects%3A+SCALE-maintenance. &rank=1 (accessed 2013 Aug 28).
22. Victoza (liraglutide) package insert. Princeton, NJ: Novo Nordisk; 2012 Apr.
23. Byetta (exenatide) package insert. Princeton, NJ: Bristol-Myers Squibb; 2013 Feb.
24. Bydureon (exenatide extended-release) package insert. Princeton, NJ: Bristol-Myers Squibb; 2013 Feb.
25. Finer N, James WP, Kopelman PG et al. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicenter study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000; 24:306-13.
26. Hauptman J, Lucas C, Boldrin MN et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000; 9:160-7.
27. Smith SR, Weissman NJ, Anderson CM et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010; 363:245-56.
28. Fidler MC, Sanchez M, Raether B et al. A one year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011; 96:3067-77.
29. Gadde KM, Allison DB, Ryan DH et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377:1341-52.
30. Allison DB, Gadde KM, Garvey WT et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2011; 20:330-42.